Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

100%

10 trials in Phase 3/4

Results Transparency

71%

5 of 7 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

10(100.0%)

10Total

Phase 3(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03287232Phase 3Completed

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Role: lead

NCT03619005Phase 3Withdrawn

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Role: lead

NCT03740945Phase 3Withdrawn

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Role: lead

NCT03782480Phase 3Unknown

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

Role: collaborator

NCT01256671Phase 3Completed

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Role: lead

NCT01846442Phase 3Completed

Topical DHEA Against Vaginal Atrophy

Role: lead

NCT01256684Phase 3Completed

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

Role: lead

NCT01358760Phase 3Completed

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

Role: lead

NCT02013544Phase 3Completed

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Role: lead

NCT01452373Phase 3Completed

Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women

Role: lead

All 10 trials loaded